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Abstract: Staging glaucomatous damage into appropriatecategories enhances management of the disease. Automated 
static perimetry is the benchmark for testing visual function in glaucoma.  Numerous examples of standard automated 
perimetry staging systems have been proposed but difficulties such as lack of accuracy, absence of information related to 
location and depth of the defect(s) and need of time-consuming analysis of every visual field test result may reduce their 
day-to-day clinical usefulness.A new visual field staging system is proposed: the University of São Paulo Glaucoma 
Visual Field Staging System (USP-GVFSS). In this system, qualitative and quantitative characteristics of the visual field 
defect are described. The method is intuitive, comprehensible and describes severity, extension and hemi field 
involvement. 
WHY STAGE GLAUCOMA PATIENT? 
  Staging glaucomatous damage into broad categories of 
damage such as, mild, moderate, and advanced enhances 
management. It promotes careful assessment and 
documentation of clinical damage, thereby facilitating 
monitoring for stability versus progression and provides a 
common language for both clinical and research purposes. 
HOW TO STAGE GLAUCOMATOUS DAMAGE? 
  Glaucomatous damage can be quantified using either 
structural or functional loss criteria, or a combination of 
both. Patients with glaucoma may present with the disease 
before damage is detectable with standard achromatic 
automated perimetry (“pre-perimetric glaucoma”) or with 
clear glaucomatous visual field defect(s). In pre-perimetric 
glaucoma, clinicians may detect structural changes. 
However, manual systems based on clinical examination are 
subjective, relatively poorly reproducible, and require 
specific clinical experience. 
  Automated computerized devices analyze and quantify 
the optic nerve and RNFL thickness objectively with good 
reproducibility. These include scanning laser 
ophthalmoscopy, scanning laser polarimetry and optical 
coherence tomography; each may quantify and allow broad 
staging of structural damage. However these expensive and 
sophisticated technologies are evolving faster than clinical 
assessment of their utility. 
Perimetric Glaucoma 
  Automated static perimetry is the benchmark for testing 
visual function in glaucoma; in the first evaluation it detects 
and quantifies damage, and in follow-up of a diagnosed   
patient, it detects stability or progression of loss. Patients 
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with perimetric glaucoma may be staged on their visual field 
sensitivities as measured by standard automated perimetry 
(SAP) based on the number and depth of defective points, 
mean deviation (MD), or most recently, the visual field 
index. While these parameters are all Humphrey perimeter 
based, other perimeter manufacturers have software that 
offers similar information. 
  An ideal method to classify functional damage in 
glaucoma should be objective, reproducible, and user- 
friendly; it should supply useful information on the 
characteristics of visual field defects (shape, type, location 
and depth), it should provide a classification which is 
consistent with structural damage data, widely accepted and 
used, and able to monitor even relatively small changes in 
functional loss over time. 
  Numerous examples of SAP staging systems have been 
proposed [1-8].
 The most common criteria used by published 
researches to stage glaucoma, is that of Hodapp, Parish and 
Anderson (H-P-A) [3]. 
  The H-P-A classification system is a clinically useful 
method that considers two criteria: the overall extent of 
damage using both MD value and the number of defective 
points in the Humphrey Statpac-2 pattern deviation 
probability map of the 24-2, SITA-STANDARD test. In 
addition the method takes into consideration, the proximity 
of defect(s) to fixation (Fig. 1). 
  Despite its popularity, this classification has some 
disadvantages: the visual field defect is characterized into 
four relatively coarse stages (Fig. 2); accurate and time-
consuming analysis of every visual field test result is 
required, reducing its day-to-day clinical usefulness; there is 
no information about the location and depth of the defect(s); 
And finally, this system may suggest a significant 
deterioration when in fact none has occurred. 
  In 2006, Mills et al. proposed a new system [8], similar 
to H-P-A with six stages. (Fig. 3) The method is considered 
less friendly than H-P-A requiring an analytical and time – 
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Fig. (1). Hoddap –Parrish –Anderson criteria. 
 
Fig. (2). All visual field defects above are classified as severe by H-P-A classification (at least one point in the central 5 degrees has a 
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consuming assessment of several visual fields; this is even 
less helpful for day-to-day clinical use. 
  A more continuous staging system suggested by the 
Advanced Glaucoma Intervention Study (AGIS) [4], 
subdivided patients’ visual fields into 20 stages, in order to 
maximize the likelihood of detecting a patient who became 
worse (Fig. 4). As it requires a computer program to simplify 
the calculation of the score, this too is impractical for routine 
clinical use. The score is obtained from the total deviation 
plot of Humphrey Visual Field Statpac2. A point is 
considered defective when a minimal amount of sensitivity 
depression is reached. 
  Similar to the AGIS score, in the Collaborative Initial 
Glaucoma Treatment Study (CIGTS) visual field score, a 
weight was given based on minimum depth of the defect at 
any given point in addition to its two most defective 
neighboring points in the total deviation probability plot of 
the Humphrey 24-2 threshold test. The score obtained from 
the 52 points in the field are summed, divided by 10.4 and 
transformed in a numerical scale. 
  H-P-A, AGIS and CIGTS visual field staging systems are 
accurate for localized defects, but they fail to account for 
subtle diffuse sensitivity depression, which sometimes may 
be due to early glaucomatous damage. 
 
  Other methods such as Brusini’s Glaucoma Staging 
System are based on SAP Indices.
6 Brusini and co-workers 
used VF indices to obtain information not only related to the 
severity of the defects, but also about the type of damage. 
The method is useful to stage the damage severity, to 
separate the different components of VF loss (generalized, 
localized and mixed) and to monitor progression over time. 
The lines that separate the different stages were 
mathematically determined and the system is comparable 
with H-P-A and AGIS methods (Fig. 5). 
  One downside of this method is that it is strictly based on 
2 global indices, and thus can be affected by artifacts and 
short-term fluctuation. In addition, it does not provide 
information about location, shape and morphology of visual 
field defects; therefore very different defects may be 
classified as similar. 
A NEW GLAUCOMA VISUAL FIELD STAGING 
SYSTEM 
  The University of São Paulo Glaucoma Visual Field 
Staging System (USP-GVFSS) proposed by Susanna and 
Vessani [9] is a new system in which qualitative and 
quantitative characteristics of the visual field defect are 
described. The system is intuitive, comprehensible and 
describes severity, extension and hemi field involvement.   
 
 
Fig. (5). Brusini et al. glaucoma staging system [6]. 
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Fig. (6). Description of USP glaucomatous visual field staging system. 
 
 
Fig. (7). (A) Extensive visual field defect involving superior hemifield (B) Paracentral visual field defect. Both defects are classified as 
severe by Hoddap Parish and Anderson criteria (any point within central 5°with sensitivity less than or equal to 0 dB). Using USP System 
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The definition of visual field defect(s) is the same as 
proposed by the H-P-A system which includes the glaucoma 
hemifield test outside normal limits or a cluster of three or 
more non-edge points in a typical location of glaucoma, all 
depressed on the pattern deviation plot at a p<5% level and 
one depressed at a p<1% level or a CPSD that occurs in less 
than 5% of normal visual fields. 
  The new system proposed includes the Visual Field 
Index (VFI), a new parameter recently introduced in the 
Humphrey Visual Field (Carl Zeiss Meditec Inc, Dublin, 
CA) [10]. 
  The advantages of the VFI include: the replacement of 
MD (dB) value with % for a full visual field, reduction of 
cataract effects, comprehensible scale ranging from 100% to 
0% (normal function to perimetric blindness), and a 
weighting procedure applied to reflect ganglion cell loss 
(central  vs. peripheral VF loss based on the cortical 
magnification factor). The Pattern Deviation probability map 
is used to identify normal and abnormal points. Points <0 dB 
are considered to have 0% sensitivity. Normal points 
have100% sensitivity. The amount of loss is then calculated 
using total deviation numerical maps. Defect depth is 
recalculated into %. 
  In USP GVFSS, VFI cut-off values are established for 
each stage. Location is considered in 3 categories: VF defect 
inside the 5 central degrees (5); VF defect inside the 10 
central degrees but outside the 5 central degrees (10); VF 
defect outside the 10 central degrees (10+). One (1) versus 
both hemifield (2) involvement is included. The relationship 
to the blind spot is based on points depressed below 0.5% 
level on the pattern deviation plot and it is characterized as 
A, if the visual field defect is not connected with the blind 
spot, or B, if the visual field defect is connected with the 
blind spot. Fig. (6) presents an example of this classification 
describing the characteristics of one glaucomatous visual 
field defect. 
  There are several advantages of the USPGSS over the 
previous methods. 
  The USP- GVFSS is easier to apply and to memorize. It 
includes, in a very compact way, a modern visual field index 
plus information about location of the defect (closeness to 
the point of fixation and association with the physiological 
blind spot). This may have clinical relevance: defects that 
evolve both hemifields may have different prognosis than 
defects that are located in only one hemifield (Fig. 7). 
  Staging visual fields meaningfully is truly challenging for 
clinicians and researchers. Fine characterization of the 
glaucomatous visual field allows for the grouping of patients 
into subtypes and stages visual field loss. This may be 
important to establish the rate and the risk of progression of 
each subtype of glaucomatous visual field loss, which is 
crucial to optimize treatment. 
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